X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
AT-007 (govorestat) is a central nervous system (CNS) penetrant Aldose Reductase inhibitor (ARI), which is in phase 3 clinical development for the treatment of Classic Galactosemia.
Lead Product(s): Govorestat
Therapeutic Area: Genetic Disease Product Name: AT-007
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 28, 2024
Details:
The Company intends to use the net proceeds to fund the clinical development of AT-007 (govorestat), a novel aldose reductase Inhibitor. It is being evaluated in patients for the treatment of Galactosemia.
Lead Product(s): Govorestat
Therapeutic Area: Genetic Disease Product Name: AT-007
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Perceptive Advisors
Deal Size: $100.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement February 28, 2024
Details:
AT-007 (govorestat) is a central nervous system (CNS) penetrant Aldose Reductase inhibitor (ARI), which is in phase 3 clinical development for the treatment of Classic Galactosemia.
Lead Product(s): Govorestat
Therapeutic Area: Genetic Disease Product Name: AT-007
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 28, 2024
Details:
AT-007 (govorestat) is a cns penetrant aldose reductase inhibitor. It is being evaluated for the treatment of hereditary neuropathy caused by SORD deficiency.
Lead Product(s): Govorestat
Therapeutic Area: Genetic Disease Product Name: AT-007
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 15, 2024
Details:
AT-001 (caficrestat) is an investigational oral, novel, potent Aldose Reductase inhibitor which is in Phase 3 clinical development for the treatment of Diabetic Cardiomyopathy.
Lead Product(s): Caficrestat
Therapeutic Area: Cardiology/Vascular Diseases Product Name: AT-001
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 04, 2024
Details:
AT-007 (govorestat) is a central nervous system (CNS) penetrant Aldose Reductase inhibitor (ARI), which is in phase 3 clinical development for the treatment of Classic Galactosemia.
Lead Product(s): Govorestat
Therapeutic Area: Genetic Disease Product Name: AT-007
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 03, 2024
Details:
AT-007 (govorestat) is a central nervous system (CNS) penetrant Aldose Reductase inhibitor (ARI) in development for the treatment of several rare neurological diseases, including Galactosemia, SORD Deficiency, and PMM2-CDG.
Lead Product(s): Govorestat
Therapeutic Area: Genetic Disease Product Name: AT-007
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 06, 2023
Details:
AT-007 (govorestat) is a central nervous system (CNS) penetrant Aldose Reductase inhibitor (ARI) in development for the treatment of several rare neurological diseases, including Galactosemia, SORD Deficiency, and PMM2-CDG.
Lead Product(s): Govorestat
Therapeutic Area: Genetic Disease Product Name: AT-007
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 25, 2023
Details:
AT-007 (govorestat) is a central nervous system (CNS) penetrant Aldose Reductase inhibitor (ARI) in development for the treatment of several rare neurological diseases, including Galactosemia, SORD Deficiency, and PMM2-CDG.
Lead Product(s): Govorestat
Therapeutic Area: Rare Diseases and Disorders Product Name: AT-007
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 25, 2023
Details:
The Company intends to use the net proceeds to fund research and development and registration of its pipeline candidates, including AT-007 (gavorestat) an investigational, novel Aldose Reductase Inhibitor (ARI) being developed for the treatment of several rare diseases.
Lead Product(s): Govorestat
Therapeutic Area: Genetic Disease Product Name: AT-007
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Venrock Healthcare Capital Partners
Deal Size: $30.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement April 24, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
